Related Experiment Video
Updated: Feb 18, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
13.4K
GRK2 as a therapeutic target for heart failure
Alessandro Cannavo1,2, Klara Komici2, Leonardo Bencivenga2
1a Center for Translational Medicine , Temple University Lewis Katz School of Medicine , Philadelphia , PA , USA.
Expert Opinion on Therapeutic Targets
|November 24, 2017
Summary
Inhibiting G protein-coupled receptor kinase-2 (GRK2) shows promise for treating heart failure (HF). Studies in animal models demonstrate GRK2 inhibition protects the heart from damage, offering new therapeutic hope for cardiovascular disease.
Area of Science:
- Cardiovascular Disease Research
- Molecular Pharmacology
- Biochemistry
Background:
- G protein-coupled receptor kinase-2 (GRK2) regulates G protein-coupled receptors (GPCRs), notably β-adrenergic receptors (ARs).
- Elevated GRK2 activity contributes to cardiovascular disease, including heart failure (HF), by impairing cardiac and adrenal AR function and other signaling pathways.
- Emerging evidence indicates GRK2 possesses non-canonical signaling roles, independent of GPCRs, through interactions with other molecules or mitochondrial localization.
Purpose of the Study:
- To review the current state of GRK2 inhibition as a therapeutic strategy for heart failure.
- To highlight the protective effects of GRK2 inhibition or deletion in preclinical models of cardiovascular disease.
Main Methods:
- Review of studies involving GRK2 inhibition or genetic deletion in animal models of cardiovascular disease.
- Analysis of GRK2's role in GPCR regulation and non-canonical signaling pathways.
Main Results:
- GRK2 inhibition and genetic deletion have demonstrated cardioprotective effects in various animal models of cardiovascular disease.
- These interventions mitigate adverse cardiac remodeling and improve cardiac function.
Conclusions:
- GRK2 represents a promising therapeutic target for heart failure.
- Inhibition of GRK2 offers a potential new strategy to combat the development and progression of HF, a leading cause of mortality worldwide.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:30Heart Failure V: Medical Management
374
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
374
01:26Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.2K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.2K
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K